Literature DB >> 27640789

[Combination of triptolide with sodium cantharidinate synergistically enhances apoptosis on
 hepatoma cell line 7721].

Yuyan Zhou1, Mingyan Wang2, Xuejuan Pan1, Zaifeng Dong1, Li Han1, Yong Ju1, Guodong Wang1.   

Abstract

OBJECTIVE: To determine the combined cytotoxic effect and the molecular basis of triptolide and sodium cantharidinate on hepatoma cell line 7721.
METHODS: After treating the hepatoma cell line 7721 with triptolide(9, 18, or 36 μg/mL) and/or sodium cantharidinate (2, 5, or 10 μg/mL), cell viability assay and apoptosis were examined by MTT and flocytometry, respectively. The protein levels of caspase 3 and nuclear factor κB were analyzed by Western blot.
RESULTS: Viability of hepatoma cell line 7721 was inhibited by either the therapy of triptolide and/or sodium cantharidinate (P<0.05) in a time- and dose-dependent manner. The combined effects of both drugs were better than those of the single drug (P<0.05). The combined therapy down-regulated the expression of NF-κB p65 (P<0.05) while up-regulated the expression of caspase-3 (P<0.05).
CONCLUSION: Triptolide and sodium cantharidinate exert a synergistic toxic effect on hepatoma cell line 7721, which is related to increasing capase-3 activity and suppression of NF- κB.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27640789     DOI: 10.11817/j.issn.1672-7347.2016.09.005

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  1 in total

1.  Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1).

Authors:  Lin Wu; Chao Deng; Hui Zhang; Jie Weng; Youhua Wu; Shan Zeng; Tiegang Tang; Peiguo Cao; Bo Qiu; Li Zhang; Huaxin Duan; Bing Zhang; Dong Zhang; Taotao Zhang; Chunhong Hu
Journal:  Front Oncol       Date:  2021-12-14       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.